

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the “Announcement in Relation to the Acceptance of a Subsidiary’s Drug Registration Application” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

3 December 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Pan Donghui and Mr. Chen Yuqing; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* for identification purposes only

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

The drug registration applications of Tao Hong Si Wu Granules (桃紅四物顆粒, the “**New Drug**”) of Hebei Wanbang Folon Pharmaceutical Co., Ltd.* (河北萬邦復臨藥業有限公司), being a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the “**Company**”), was accepted by the National Medical Products Administration recently.

II. General information and research progress of the New Drug

The New Drug is a Category 3.1 innovative traditional Chinese medicine. Its main functions are nourishing blood, activating blood circulation and removing blood stasis, and is intended to be used for blood deficiency and blood stasis syndrome, the symptoms of which include irregular menstruation, heavy menstrual flow with clots, purple and sticky menstrual blood, abdominal pain and bloating, etc. The prescription of the New Drug comes from the formulation named Tao Hong Si Wu Decoction (桃紅四物湯) in the "Fu Ke Bing Jian"(《婦科冰鑒》) written by Chai Dehua (柴得華) from the Qing Dynasty, and has been listed in the "Catalogue of Ancient Classic Famous Recipes (First Batch)" (《古代經典名方目錄(第一批)》) by the National Administration of Traditional Chinese Medicine.

As of October 2024, the Group (i.e., the Company and its subsidiaries/units, the “**Group**”) has invested approximately RMB3.72 million (unaudited) in total in the research and development of the New Drug at current stage.

As of the date of this Announcement (i.e. 3 December 2024), no Tao Hong Si Wu Granules have been approved for marketing in China (excluding Hong Kong, Macao, and Taiwan regions).

III. Risk Warning

The New Drug is subject to, among others, the passing of the GMP compliance inspection and the drug registration approval before commercial production. This acceptance of the drug registration application will not have a material impact on the results of the Group at this stage.

Due to the industry characteristics of the pharmaceutical products, the specific sales performance after the market launch of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

3 December 2024

** For identification purposes only*